<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03905343</url>
  </required_header>
  <id_info>
    <org_study_id>SAKK 21/18</org_study_id>
    <secondary_id>2018-003648-22</secondary_id>
    <nct_id>NCT03905343</nct_id>
  </id_info>
  <brief_title>Ribociclib-endocrine Combination Therapy Versus Chemotherapy as 1st Line in Visceral mBC</brief_title>
  <official_title>Ribociclib-endocrine Combination Therapy Versus Chemotherapy as 1st Line Treatment in Patients With Visceral Metastatic Breast Cancer. A Multicenter, Randomized Phase III Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swiss Group for Clinical Cancer Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Belgian Society of Medical Oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Swiss Group for Clinical Cancer Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this trial is to assess if patients treated with the combination of ribociclib and
      endocrine therapy respond to treatment as fast as patients treated with chemotherapy only,
      without decreasing their quality of life (QoL).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Breast cancer is the most frequent malignancy in women and the leading cause of cancer
      mortality in most countries in Europe. Metastatic breast cancer remains an incurable disease
      with a median overall survival (OS) of 2-4 years and a 5-year survival of only 25%. Patients
      with hormone receptor (HR)-positive breast cancer involving visceral disease at diagnosis
      have an even worse outcome.

      Many oncologists still prefer to treat visceral disease primarily with chemotherapy rather
      than with endocrine treatment, thinking to receive a faster response with chemotherapy than
      with endocrine therapy, especially in patients with clinical symptoms or potentially
      threatening lesions. However, results from cross-sectional clinical practice studies suggest
      that endocrine therapy is associated with better quality of life, fewer concerns about side
      effects, less activity impairment and higher treatment satisfaction compared to chemotherapy.
      In addition, with the new data of CDK4/6 inhibitors combined with endocrine treatment there
      is an even better efficacy data available compared to endocrine therapy alone.

      The aim of this trial is to assess if patients treated with the combination of ribociclib and
      endocrine therapy respond to treatment as fast as patients treated with chemotherapy only,
      without decreasing their quality of life (QoL).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 25, 2019</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">December 2026</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is an international, multicenter, open-label, randomized phase III trial.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of life-adjusted early disease control</measure>
    <time_frame>at 12 weeks.</time_frame>
    <description>A patient will be counted as a success for this endpoint when during the first 12 weeks
- the response according to RECIST v1.1 is stable disease or better.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life-adjusted early disease control</measure>
    <time_frame>at 12 weeks.</time_frame>
    <description>A patient will be counted as a success for this endpoint when during the first 12 weeks
- the QoL according Functional Assessment of Cancer Therapy-Breast Trial Outcome Index [FACT-B TOI] score does not worsen by 5 points or more.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Control (DC) at 12 weeks</measure>
    <time_frame>week 6, 12.</time_frame>
    <description>A patient will be counted as a success for this endpoint when during the first 12 weeks the response according to RECIST v1.1 is stable disease or better. Patients with missing response assessments within the first 12 weeks will be counted as failure unless there was no progressive disease (PD) documented within the first 12 weeks and the first subsequent assessment also shows no PD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>week 6, 12, then every 12 weeks up to 3 years or end of trial treatment.</time_frame>
    <description>ORR is defined as the proportion of patients having achieved complete response (CR) or partial response (PR) during trial treatment. Response will be evaluated according to RECIST v1.1 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to objective response (OR)</measure>
    <time_frame>week 6, 12, then every 12 weeks up to 3 years or end of trial treatment.</time_frame>
    <description>Time to OR will be calculated from randomization until first documented CR or PR according to RECIST v1.1 criteria. Time to OR will be calculated for patients having achieved a CR or PR at any time during trial treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>week 6, 12, then every 12 weeks up to 3 years.</time_frame>
    <description>PFS is defined as the time from randomization until progression according the RECIST v1.1 criteria or death from any cause, whichever occurs first. Patients not having an event at the time of analysis as well as patients starting a new anti-cancer therapy in the absence of an event will be censored at the date of their last tumor assessment before starting a new anti-cancer treatment, if any.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure (TTF)</measure>
    <time_frame>week 6, 12, then every 12 weeks up to 3 years.</time_frame>
    <description>TTF is defined as the time from randomization until stopping of trial treatment from any cause. Patients not having an event at the time of analysis will be censored at the date of their last known date of trial treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) at 3 years</measure>
    <time_frame>week 6, 12, then every 12 weeks up to 3 years.</time_frame>
    <description>OS at 3 years is determined by the Kaplan-Meier estimator for OS at 3 years. OS is defined as time from randomization to death due to any cause. Any patient not known to have died at the time of analysis will be censored based on the last recorded date on which the patient was known to be alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in overall QoL (FACT-B) until 24 months</measure>
    <time_frame>Changes from baseline to 24 months</time_frame>
    <description>Changes in Functional Assessment of Cancer Therapy-Breast (FACT-B) total score (score range 0-148, higher scores indicate better quality of life)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to QoL deterioration</measure>
    <time_frame>From baseline to 24 months</time_frame>
    <description>Time to QoL deterioration is defined as the duration between baseline and first occurrence of a decrease of ≥ 5 points in the FACT-TOI score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to QoL improvement</measure>
    <time_frame>From baseline to 24 months</time_frame>
    <description>Time to QoL improvement is defined as the duration between baseline and first occurrence of an increase of ≥ 5 points in the FACT-TOI score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to pain improvement</measure>
    <time_frame>From baseline to 24 months</time_frame>
    <description>Improvements in pain will be assessed up to 24 months by the item pain severity of the Brief Pain Inventory (BPI), scale range: 0= no pain to 10 = pain as bad as one can imagine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AEs)</measure>
    <time_frame>every 4 weeks up to 3 years.</time_frame>
    <description>All AEs will be assessed according to NCI CTCAE v5.0.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>A: endocrine therapy + ribociclib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B: mono-chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribociclib</intervention_name>
    <description>Ribociclib 600mg p.o. d1-21, q4w in combination with endocrine treatment for 3 years.</description>
    <arm_group_label>A: endocrine therapy + ribociclib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Mono-chemotherapy</intervention_name>
    <description>mono-chemotherapy for at least 12 weeks (afterwards, maintenance endocrine therapy ± ribociclib inhibitor is allowed) and up to 3 years.</description>
    <arm_group_label>B: mono-chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Endocrine-Therapy</intervention_name>
    <description>The choice of endocrine therapy is up to the investigator, but the chosen endocrine therapy has to be registered to be used in combination with ribociclib in the investigated indication.</description>
    <arm_group_label>A: endocrine therapy + ribociclib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent according to national law and ICH/GCP regulations before
             registration and prior to any trial specific procedures

          -  Histologically or cytologically confirmed diagnosis of HR-positive (ER+ ≥10%),
             HER2-negative advanced stage breast cancer

          -  Measurable visceral disease according to RECIST v1.1. Visceral disease in liver and/or
             lung. Peritoneal and/or pleural metastases only are accepted, with the condition to be
             measurable

          -  No previous systemic anticancer therapy for metastatic disease allowed

          -  Mono-chemotherapy is a reasonable treatment option

          -  Patients with a prior malignancy and treated with curative intention are eligible if
             all treatment of that malignancy was completed at least 2 years before randomization
             and the patient has no evidence of disease at randomization. Less than 2 years is
             acceptable for adequately treated cervical carcinoma in situ or localized non-melanoma
             skin cancer

          -  Patients with asymptomatic and stable (treated or untreated) central nervous system
             (CNS) metastases are eligible, provided they meet the following criteria:

               -  ≤ 5 CNS lesions with a maximum diameter of the largest lesion of 10 mm

               -  No evidence of progression at registration compared to the latest brain imaging
                  (if applicable)

               -  No ongoing requirement for corticosteroids as therapy for CNS disease

          -  Baseline QoL and pain questionnaires have been completed within 21 days prior to
             registration

          -  Postmenopausal women (without ovarian function suppression)

          -  Age ≥ 18 years

          -  WHO performance status 0-2

          -  Adequate bone marrow function: neutrophil count ≥ 1.5 x 109/L, platelet count ≥ 100 x
             109/L, hemoglobin ≥ 90 g/L

          -  Adequate hepatic function: bilirubin ≤ 1.5 x ULN (except for patients with Gilbert's
             disease ≤ 3.0 x ULN), AST ≤ 2.5 x ULN, AP ≤ 2.5 x ULN

          -  Adequate renal function: estimated glomerular filtration rate (eGFR) &gt; 40
             mL/min/1.73m2 (according to CKD-EPI or MDRD formula)

          -  Patient is able and willing to swallow trial drug as whole tablet

        Exclusion Criteria:

          -  Visceral crisis (clinical judgment of treating investigator based on the ABC
             consensus: &quot;visceral crisis is defined as severe organ dysfunction as assessed by
             signs and symptoms, laboratory studies, and rapid progression of disease. Visceral
             crisis is not the mere presence of visceral metastases, but implies important visceral
             compromise leading to a clinical indication for a more rapidly efficacious therapy,
             particularly since another treatment option at progression will probably not be
             possible&quot;)

          -  Symptomatic brain metastases indicative of active disease (defined as new and/or
             progressive brain metastases at the time of study entry) or leptomeningeal disease

          -  Any prior systemic anti-cancer treatment for advanced stage breast cancer

          -  Prior treatment with adjuvant CDK4/6 inhibitor

          -  Concurrent or recent (within 30 days of randomization) treatment with any other
             experimental drug. Exception: participation in SAKK 96/12 is allowed

          -  Concomitant use of other anti-cancer drugs or radiotherapy, except for local pain
             control

          -  Planned surgery of metastatic sites in the first 12 treatment weeks

          -  Severe or uncontrolled cardiovascular disease (congestive heart failure NYHA III or
             IV), unstable angina pectoris, history of myocardial infarction within the last six
             months, serious arrhythmias requiring medication (with exception of atrial
             fibrillation or paroxysmal supraventricular tachycardia)

          -  Electrocardiogram (ECG) abnormalities of Q-wave infarction (unless identified ≥ 6
             months prior to randomization), or QTc interval &gt;450 msec. The use of concomitant
             medications with a known significant risk of prolonging the QT interval or inducing
             Torsades de pointes is not allowed

          -  Any concomitant drugs contraindicated for use with the trial drugs according to the
             approved national product information

          -  Known hypersensitivity to trial drug(s) or to any component of the trial drug(s)

          -  Any other serious underlying medical, psychiatric, psychological, familial or
             geographical condition, which in the judgment of the investigator may interfere with
             the planned staging, treatment and follow-up, affect patient compliance or place the
             patient at high risk from treatment-related complications
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Ruhstaller, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Kantonsspital St. Gallen - Breast Center St. Gallen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karin Rothgiesser, PhD</last_name>
    <phone>+41 31 389 91 91</phone>
    <email>trials@sakk.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinique-Saint-Pierre</name>
      <address>
        <city>Ottignies</city>
        <zip>1340</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lionel Duck, MD</last_name>
      <phone>+32 10 437 965</phone>
      <email>lionel.duck@cspo.be</email>
    </contact>
    <investigator>
      <last_name>Lionel Duck, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Baden</name>
      <address>
        <city>Baden</city>
        <zip>5404</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clemens Caspar, MD</last_name>
      <phone>+41 56 486 27 62</phone>
      <email>clemens.caspar@ksb.ch</email>
    </contact>
    <investigator>
      <last_name>Clemens Caspar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Baden</name>
      <address>
        <city>Baden</city>
        <zip>CH-5404</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clemens B. Caspar, MD</last_name>
      <phone>41-56-486-2762</phone>
      <email>clemens.caspar@ksb.ch</email>
    </contact>
    <investigator>
      <last_name>Clemens Caspar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitaetsspital-Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoph Rochlitz, Prof</last_name>
      <phone>+41 61 265 50 74</phone>
      <email>crochlitz@uhbs.ch</email>
    </contact>
    <investigator>
      <last_name>Christoph Rochlitz, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brustzentrum Basel - Praxis für ambulante Tumortherapie</name>
      <address>
        <city>Basel</city>
        <zip>4052</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Roger Thorn, MD</last_name>
      <phone>+41 61 279 98 22</phone>
      <email>dr.david.thorn@hin.ch</email>
    </contact>
    <investigator>
      <last_name>David Roger Thorn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico della Svizzera Italiana - Ospedale Regionale Bellinzona e Valli</name>
      <address>
        <city>Bellinzona</city>
        <zip>6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosaria Condorelli, MD</last_name>
      <phone>+41 91 811 48 41</phone>
      <email>rosaria.condorelli@eoc.ch</email>
    </contact>
    <investigator>
      <last_name>Rosaria Condorelli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inselspital Bern</name>
      <address>
        <city>Bern</city>
        <zip>CH-3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuela Rabaglio, MD</last_name>
      <phone>+41 31 632 43 70</phone>
      <email>manuela.rabaglio@insel.ch</email>
    </contact>
    <investigator>
      <last_name>Manuela Rabaglio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Graubuenden</name>
      <address>
        <city>Chur</city>
        <zip>CH-7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roger von Moos, MD</last_name>
      <phone>41-81-256-6111</phone>
      <email>roger.vonmoos@ksgr.ch</email>
    </contact>
    <investigator>
      <last_name>Roger von Moos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique des Grangettes</name>
      <address>
        <city>Chêne-Bougeries</city>
        <zip>1224</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samuel Blaser, MD</last_name>
      <phone>+41 22 545 80 16</phone>
      <email>samuel.blaser@grangettes.ch</email>
    </contact>
    <investigator>
      <last_name>Samuel Blaser, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital neuchâtelois</name>
      <address>
        <city>La Chaux-de-Fonds</city>
        <zip>2300</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agnès Auteri, MD</last_name>
      <phone>+41 79 559 41 93</phone>
      <email>agnes.auteri@h-ne.ch</email>
    </contact>
    <investigator>
      <last_name>Agnès Auteri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <zip>CH-1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Khalil Zaman, MD</last_name>
      <phone>41-21-314-4658</phone>
      <email>khalil.zaman@chuv.ch</email>
    </contact>
    <investigator>
      <last_name>Khalil Zaman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Liestal</name>
      <address>
        <city>Liestal</city>
        <zip>CH-4410</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bettina Seifert, MD</last_name>
      <phone>+41 61 925 34 03</phone>
      <email>bettina.seifert@ksli.ch</email>
    </contact>
    <investigator>
      <last_name>Bettina Seifert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Luzern</name>
      <address>
        <city>Luzern</city>
        <zip>6000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ralph Winterhalder, MD</last_name>
      <phone>+41 41 205 58 75</phone>
      <email>ralph.winterhalder@ksl.ch</email>
    </contact>
    <investigator>
      <last_name>Ralph Winterhalder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hirslanden Klinik St. Anna Luzern</name>
      <address>
        <city>Luzern</city>
        <zip>6006</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Spirig, MD</last_name>
      <phone>+41 41 208 32 10</phone>
      <email>Christian.Spirig@hirslanden.ch</email>
    </contact>
    <investigator>
      <last_name>Christian Spirig, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Onkologie Zentrum Spital Männedorf</name>
      <address>
        <city>Männedorf</city>
        <zip>8708</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Hochstrasser, MD</last_name>
      <phone>+41 44 922 30 00</phone>
      <email>a.hochstrasser@spitalmaennedorf.ch</email>
    </contact>
    <investigator>
      <last_name>Andreas Hochstrasser, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Olten</name>
      <address>
        <city>Olten</city>
        <zip>4600</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catrina Uhlmann Nussbaum, MD</last_name>
      <phone>+41 62 311 42 41</phone>
      <email>cuhlmann_ol@spital.ktso.ch</email>
    </contact>
    <investigator>
      <last_name>Catrina Uhlmann Nussbaum, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital de Sion</name>
      <address>
        <city>Sion</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Véronique Membrez, MD</last_name>
      <phone>+41 27 603 48 53</phone>
      <email>veronique.membrez@hopitalvs.ch</email>
    </contact>
    <investigator>
      <last_name>Véronique Membrez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brustzentrum Ostschweiz</name>
      <address>
        <city>St. Gallen</city>
        <zip>9016</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Ruhstaller, Prof</last_name>
      <phone>+41 71 552 33 30</phone>
      <email>Thomas.ruhstaller@bz-ost.ch</email>
    </contact>
    <investigator>
      <last_name>Thomas Ruhstaller, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital - St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <zip>CH-9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ursula Hasler-Strub, MD</last_name>
      <phone>+41 71 494 11 11</phone>
      <email>Ursula.Hasler-Strub@kssg.ch</email>
    </contact>
    <investigator>
      <last_name>Ursula Hasler-Strub, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spital STS AG</name>
      <address>
        <city>Thun</city>
        <zip>3600</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoph Ackermann, MD</last_name>
      <phone>+41 58 636 26 45</phone>
      <email>christoph.ackermann@spitalstsag.ch</email>
    </contact>
    <investigator>
      <last_name>Christoph Ackermann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Winterthur, Brustzentrum</name>
      <address>
        <city>Winterthur</city>
        <zip>8401</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Müller, MD</last_name>
      <phone>+41 52 266 25 52</phone>
      <email>andreas.mueller@ksw.ch</email>
    </contact>
    <investigator>
      <last_name>Andreas Müller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Onkologie Bellevue</name>
      <address>
        <city>Zurich</city>
        <zip>8001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Basil A. Bättig, MD</last_name>
      <phone>+41 44 261 61 11</phone>
      <email>bbaettig@hin.ch</email>
    </contact>
    <investigator>
      <last_name>Basil A. Bättig, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OnkoZentrum Zürich AG - Klinik im Park</name>
      <address>
        <city>Zürich</city>
        <zip>8038</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Kralidis, MD</last_name>
      <phone>+41 43 344 33 33</phone>
      <email>elena.kralidis@ozh.ch</email>
    </contact>
    <investigator>
      <last_name>Elena Kralidis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitäts Spital Zürich</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Konstantin Dedes, MD</last_name>
      <phone>+41 44 255 11 11</phone>
      <email>konstantin.dedes@usz.ch</email>
    </contact>
    <investigator>
      <last_name>Konstantin Dedes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 12, 2019</study_first_submitted>
  <study_first_submitted_qc>April 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2019</study_first_posted>
  <last_update_submitted>June 29, 2020</last_update_submitted>
  <last_update_submitted_qc>June 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>Visceral metastatic breast cancer</keyword>
  <keyword>Ribociclib</keyword>
  <keyword>Ribociclib-endocrine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

